Preclinical evaluation of a paclitaxel-incorporated nanoparticle-coated balloon in rabbit and porcine models.
The main drawback of current available drug coated balloons (DCB) is that a certain percentage of the coated drug is lost in the bloodstream during its delivery to the target lesion. We integrated the nanoparticle-mediated drug delivery technology and polydimethylsiloxane (PDMS) as a new excipient to facilitate an efficient drug delivery and uptake by endothelial cells. The present study aimed to evaluate the efficacy of the new DCB.;The novel DCB were coated with 5.6mg of paclitaxel-incorporated nanoparticles using PDMS.